Virological confirmation of concurrent dengue virus serotypes 1 and 4 by virus isolation using Fc-gamma receptor-expressing BHK cells Dengue virus (DENV) is estimated to infect approximately 400 million people annually. In 2014, 160 cases of autochthonous and 173 imported DENV infection cases were confirmed in Japan.
A serum sample from a dengue patient who returned to Japan from a visit to Cambodia in 2013, was positive for DENV-1 (genotype 1; Genbank Accession number AB873104) and DENV-4 (genotype 1; Genbank Accession number AB873105) virus genome, and negative for anti-DENV IgM and IgG. 5 Initial attempts to isolate and separate DENV using non FcgR-expressing Vero and BHK cells resulted in the isolation of DENV-1 only. To isolate DENV-4, the patient's serum sample was treated with pooled human serum samples with neutralizing activity to DENV-1 but not to DENV-4 (DENV-1 PRNT 50 1:10, DENV-4 PRNT 50 < 10; as determined by FcgR-expressing BHK cells). 6 DENV-1 and DENV-4 strains were isolated and separated, and confirmed by RT-PCR and sequencing of the E-protein gene 7 (Table 1) .
Neutralizing antibodies to one DENV serotype may possess antibody-dependent enhancement (ADE) activity to heterologous serotypes in FcgR-positive cells, resulting in higher levels of progeny virus production. 8 ADE activity also hampers serotype cross-reactive neutralizing antibody titers in FcgR-expressing cells but not in FcgR-negative cells. 6 In the present study, both neutralization and the ADE mechanism were applied to virus isolation in a concurrent infection using FcgR-expressing cells. The serotype cross-reactive pooled serum samples used in this study demonstrated high levels of neutralizing antibody to DENV-1 but no neutralizing activity to DENV-4 using FcgRexpressing cells as assay cells. 6 Thus, serotype-specific antibodies specifically neutralized the dominant DENV-1 serotype and may have enhanced the growth of the subdominant DENV-4 serotype.
In conclusion, this report provides concrete evidence of concurrent DENV infection by multiple DENV serotypes in a DENV patient, and presents evidence on the potential of viremic travelers to introduce more than a single virus serotype to the local mosquito vector population.
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